Nitazoxanide

  • TRADE NAMES: Alinia (Romark); Cryptaz
  • INDICATIONS: Diarrhea caused by Cryptosporidium parvum or Giardia lamblia (in children)
  • CLASS: Antimicrobial, Antiprotozoal
  • HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: B

Under investigation for treating COVID-19

See adverse reactions attributed to class:

Antimicrobial

Diaphoresis <1%

(package insert)

Pruritus (itching) <1%

(package insert)

Salivary gland enlargement <1%

(package insert)

Fever (pyrexia) 

(2012): Speich B+, PLoS Negl Trop Dis 6(6), e1685

Headache 

(2014): Haffizulla J+, Lancet Infect Dis 14(7), 6096–8%

(2012): Speich B+, PLoS Negl Trop Dis 6(6), e1685

Vertigo / dizziness <1%

(2012): Speich B+, PLoS Negl Trop Dis 6(6), e1685

Abdominal pain 

(2012): Speich B+, PLoS Negl Trop Dis 6(6), e1685

(2002): Stockis A+, Int J Clin Pharmacol Ther 40(5), 221

(1999): Rodriguez-Garcia R+, Rev Gastroenterol Mex 64(3), 122

Diarrhea 

(2014): Haffizulla J+, Lancet Infect Dis 14(7), 6092–8%

(2012): Speich B+, PLoS Negl Trop Dis 6(6), e1685

Nausea 

(2012): Speich B+, PLoS Negl Trop Dis 6(6), e1685

Vomiting  

(2012): Speich B+, PLoS Negl Trop Dis 6(6), e1685

Asthenia / fatigue 

(2012): Speich B+, PLoS Negl Trop Dis 6(6), e1685

Scleral pigmentation <1%

(pale-yellow) (package insert)

Rhinitis <1%

(package insert)

Adverse effects 

(2013): Basu PP+, Hepatol Res 43(6), 589 (with PEG-interferon and ribavirin)

Infection <1%

(package insert)



Adverse reactions attributed to entire drug class Antimicrobial

Page last updated 10/29/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top